BIO Special: New vision for immunotherapy, Detlev Biniszkiewicz, Founder & CEO, NextPoint Tx
Synopsis: Detlev Biniszkiewicz is the Founder and CEO of NextPoint Therapeutics, a company advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Detle...
7 Kesä 202334min
BIO Special: Advancing kidney disease care, Eric Dobmeier, President & CEO, Chinook Tx
Synopsis: Eric Dobmeier is the President and CEO of Chinook Therapeutics, a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe ...
6 Kesä 202340min
BIO Special: Advancing heart disease treatment, Faraz Ali, CEO, Tenaya Therapeutics
Synopsis: Faraz Ali is the CEO of Tenaya Therapeutics, a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlyin...
5 Kesä 202338min
Drugging the undruggable with Gregory Verdine, Co-Founder, President & CEO, Lifemine Tx & FogPharma
Synopsis: Gregory Verdine, Ph.D., is the Co-Founder, President and CEO of LifeMine Therapeutics and FogPharma. LifeMine Therapeutics is reinventing drug discovery by mining genetically-encoded small...
31 Touko 202346min
Pioneering precision therapies for cancer & blood disorders, Kate Haviland, CEO, Blueprint Medicines
Synopsis: Kate Haviland is the CEO of Blueprint Medicines, a global precision therapy company that creates life-changing medicines for people with cancer and blood disorders. Applying an approach th...
30 Touko 202327min
Targeting highly dynamic proteins to develop precision medicines, Asit Parikh, Pres. & CEO, MOMA Tx
Synopsis: Asit Parikh, M.D., Ph.D., is the President and CEO of MOMA Therapeutics, a biotech company discovering the next generation of precision medicines by targeting highly dynamic proteins that ...
24 Touko 202330min
RNA-guided programmable therapeutics for fibrosis, Samir Ounzain, CEO & Co-Founder, HAYA Tx
Synopsis: Samir Ounzain is the CEO and Co-Founder of HAYA Therapeutics, a precision medicines company developing RNA-guided programmable therapeutics targeting the regulatory genome for serious heal...
17 Touko 202326min
Single-course gene editing for cardiovascular disease, Sekar Kathiresan, Co-Founder & CEO, Verve Tx
Synopsis: Sekar Kathiresan is the Co-Founder, CEO and Board Member of Verve Therapeutics, a clinical-stage biotechnology company developing gene editing medicines to treat patients with cardiovascula...
10 Touko 202331min
